You are here

Adoxa Acne Therapy Now Available in 75 mg Tablets

MALVERN, Pa., June 2 /PRNewswire/ -- Bioglan Pharmaceuticals Company today announced that ADOXA™ (doxycycline) Tablets are now available in a 75mg tablet, adding a middle-range dosage option to Bioglan's popular 50mg and 100mg tablets currently prescribed for acne therapy.

The addition of the new 75mg tablet offers dermatologists greater flexibility in prescribing a daily acne treatment regimen. All three ADOXA™ Tablet strengths are small, easy-to-swallow, film-coated tablets, making them ideal for patients who have trouble swallowing capsules.

ADOXA™ Tablets are the first and only doxycycline tablets for the adjunctive treatment of severe acne. A broad-spectrum, second-generation tetracycline, ADOXA™ offers a small, easy-to-swallow tablet alternative to traditional doxycycline capsules.

Oral antibiotics, such as ADOXA™ Tablets, are prescribed as an adjunctive therapy for the treatment of severe acne. These medications work by suppressing the common bacteria known as P. acnes in the skin, reducing sebum production and exfoliating dead skin cells to promote new cell growth.

Bioglan Pharmaceuticals Company is a specialty pharmaceutical company with its primary therapeutic focus on prescription dermatology products. Bioglan's headquarters are located in Malvern, Pennsylvania. Bioglan is a wholly owned subsidiary of Quintiles Transnational .

ADOXA™ (doxycycline) Tablets are contraindicated in persons who have shown any sensitivity to any of the tetracyclines. The use of drugs of the tetracycline class during tooth development (last half of pregnancy, infancy, and childhood to eight years) may cause permanent discoloration of the teeth (yellow-gray-brown). Photosensitivity manifested by an exaggerated sunburn has been observed in some individuals taking tetracyclines. Treatment should be discontinued at first evidence of skin erythema. Concurrent use of tetracycline may render oral contraceptives less effective.

For full prescribing information for ADOXA™ (doxycycline) Tablets or for more information about Bioglan, call 1-888-BIOGLAN or visit .

More Headlines

However, patent dispute will delay one launch
Some experts still opposed to “right to try” treatments
Approval acquired through tropical disease priority review voucher program
FDA questioning the pharmacokinetics of psoriasis lotion Duobrii
Therapy approved for adults and children with refractory PMBCL or who have relapsed after two or more prior lines of therapy
Latest failure brings amyloid hypothesis into question
Guidance published on how to best design coverage for treatment of the smallest, most vulnerable victims of the opioid crisis
Agency plans to respond after receipt of letter of concern
Continuous nerve stimulation helps to alleviate withdrawal symptoms